Lynch Regenerative Medicine, Inc. Launched to Revolutionize the Skincare Market

Proven, patented technology drives new company’s entry into aesthetic skin rejuvenation and wound-care regenerative markets

FRANKLIN, Tenn.--(BUSINESS WIRE)-- Dr. Samuel Lynch, DMD and DMSc, a serial biotechnology entrepreneur, has announced the launch of Lynch Regenerative Medicine, Inc. (LRM), a new advanced biotherapeutics skincare company targeting unmet clinical needs in both the aesthetic and advanced wound care markets.

LRM is leveraging its proven technology, rhPDGF (Manufactured Platelet-Derived Growth Factor), the body’s most important protein promoting healing, for treatment of major underserved skin conditions, targeting improved aesthetics and healing of skin wounds. This market exceeds 41 million patients and $100 billion in annual treatment spends.

Lynch’s patented technology is a proprietary form of the human body’s own healing factor that stimulates cell and tissue growth and improved blood supply, leading to improved skin appearance and health. The technology is already employed in four FDA-approved products used in orthopedics and oral surgery. Lynch discovered the therapeutic benefits of this natural protein, and has patented and led the development of multiple novel products based on the protein in companies he has founded and led. The foundation of LRM is a natural progression of Lynch’s passion spanning more than two decades developing and delivering clinical solutions that have improved the lives of millions of patients.

“I am thrilled to announce the formation of Lynch Regenerative Medicine,” said Lynch. “Skin is the largest organ in the body, and is therefore our biggest opportunity yet to utilize the powers of rhPDGF to improve the emotional and physical health of people around the world. By harnessing the power of our highly successful regenerative technology to naturally stimulate growth of the person’s own stem cells, we have the potential to revolutionize both cosmetic and prescription-strength skin therapies and thereby help millions of patients attain healthier, more attractive appearance and heal skin injuries faster.”

Lynch received his Doctorate of Medical Sciences from Harvard University Medical School, where he initially developed the technology. He founded and subsequently sold two companies, BioMimetic Therapeutics and Lynch Biologics, both of which use rhPDGF in FDA-approved therapies for tissue and skeletal regeneration. Lynch is also the co-founder and chairman of BioTN and a founding board member of Vanderbilt University Medical Center.

“LRM’s products have the potential to disrupt the skincare industry as we know it today,” said Ben Perkins, managing partner of pHPartners, an investment banking firm specializing in life sciences transactions. “LRM’s rhPDGF has been tested, verified and FDA-approved as a revolutionary regenerative-care product for millions of patients around the world in multiple indications. We are excited to work with LRM as they bring this amazing technology to skincare. People who need comprehensive skincare will now have a better option to improve their youthful appearance and heal their skin injuries.”

LRM is in the process of building manufacturing capacity for large-scale, commercial production for its aesthetics and wound care therapies, and is currently evaluating its pure, natural products in a variety of applications to improve skincare. The new products are not yet available to the public. For more information visit www.LynchRegen.com.

About Lynch Regenerative Medicine

Founded in 2023 by Dr. Samuel Lynch, Lynch Regenerative Medicine is a biotherapeutics company pioneering innovative treatments to revolutionize skincare, including rejuvenation to achieve optimum aesthetics and regeneration to achieve improved healing of skin wounds. Its core technology utilizes patented formulations of rhPDGF (Manufactured Platelet-Derived Growth Factor), the body’s most important healing protein, to improve aesthetics and healing. LRM is currently evaluating its natural, pure protein technology in a variety of skin applications. For investor relations, please contact us at contact@LynchRegen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230907227899/en/